MedTrace Logo

Korean Post-marketing Surveillance for Reyataz®

NCT01450605 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 601

Last updated 2016-04-21

No results posted yet for this study

Summary

The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Reyataz® so that the regulatory authority can manage the marketing approval properly

Conditions

Interventions

DRUG

No Intervention

Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01450605 on ClinicalTrials.gov